MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.
- Mechanism
- Curator reviewed
MLN2222 is a proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway. Complement activation is believed to contribute to harmful inflammatory responses to heart bypass surgery that can result in significant complications; MLN2222 is being developed to reduce the incidence of death and heart attacks in patients undergoing procedures involving the use of cardiopulmonary bypass (CPB), a heart-lung bypass machine.
- Primary indication
- Investigated for use/treatment in coronary artery disease.Curator reviewed
- Code names
- CAB-2 · MLN 2222
Resolves to
What you can answer from here — as of March 06, 2025
Which drugs share a target with MLN2222, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account